NGene Therapeutics plans to file its BLA for its lead bladder cancer therapy by the end of this year, with approval expected by the end of 2027. The FDA agreed on key statistical analysis plan points that will cut the label database from 125 patients to 120. The company reported $246 million in cash.
ENGN · enGene Therapeutics Inc.
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Codification ("ASC") 205-40, Going Concern, the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects that its existing cash, cash equivalents and marketable securities as of April 30, 2026 will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months.”View the 10-Q filed Jun 15, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 50%
- Last earnings
- Nov 12, 2026
- Latest filing
- 10-Q · Sep 8
- Price history
- Feb 2022 to Nov 2026
Latest documents
enGene's non-viral gene therapy for bladder cancer lifted its complete response rate from 54% to 56%. It plans to file a BLA by the end of this year and expects approval in 2027.
enGene Therapeutics Inc. reported 56% complete response at any time for detalimogene in Cohort 1 of Phase 2 LEGEND, with 43% Kaplan-Meier estimated duration of response of at least 12 months and plans to initiate BLA filing in 4Q 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Addressable NMIBC BCG-unresponsive patients | 20,000 | November 2026 | — |
| Bladder Cancer Urologists | 11,000 | November 2026 | — |
| Bladder spasm | 13% | as of 29 October 2026 | — |
| CR at any time | 56% | October 29, 2026 | — |
| CRs occurred at first assessment | 91% | 29 October 2026 | — |
| Discontinuation | 1% | 29 October 2026 | — |
| Dose Interruption | 4% | 29 October 2026 | — |
| Dysuria | 16% | as of 29 October 2026 | — |
| EE patients remain free from cystectomy | 86% | 29 October 2026 | — |
| EE patients were free from progression to ≥T2 disease | 97% | 29 October 2026 | — |
| efficacy-evaluable patients enrolled in Cohort 1 | 120 | October 29, 2026 | — |
| Fatigue | 21% | as of 29 October 2026 | — |
| Landmark 12-month CR rate | 24% | October 29, 2026 | — |
| Median duration of complete response | 10.1 | October 29, 2026 | — |
| Median follow-up for responders | 12 | October 29, 2026 | — |
| Median follow-up of all EE Population patients | 7.5 | 29 October 2026 | — |
| Micturition urgency | 13% | as of 29 October 2026 | — |
| Of those with TRAEs, percent that were Grade 1-2 | 93% | 29 October 2026 | — |
| patients assessed for safety in Cohort 1 | 125 | October 29, 2026 | — |
| patients enrolled in Cohort 1 | 125 | October 29, 2026 | — |
| patients experiencing a serious TRAE | 2% | October 29, 2026 | — |
| patients experiencing at least one TRAE | 59% | October 29, 2026 | — |
| patients experiencing Grade 3 TRAE | 4% | October 29, 2026 | — |
| Patients in community practices | 75% | November 2026 | — |
| Pollakiuria | 16% | as of 29 October 2026 | — |
| Practicing Urologists | 14,600 | November 2026 | — |
| Preliminary Kaplan-Meier Estimate of DoR ≥12 months | 43% | October 29, 2026 | — |
| Responders remain free from cystectomy | 96% | 29 October 2026 | — |
| Responders were free from progression to ≥T2 disease in the bladder | 100% | 29 October 2026 | — |
| treat bladder cancer | 75% | as of 29October2026 | — |
| Urinary tract infection | 10% | as of 29 October 2026 | — |
| Cash, cash equivalents and marketable securities | $266.3M | As of July 31, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENGN
this stock
enGene Therapeutics Inc.
|
$116.61M | -80.7% | — | — | 2.4% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 19, 2026
- This year
- 26
NGene Therapeutics plans to file its BLA for its lead bladder cancer therapy by the end of this year, with approval expected by the end of 2027. The FDA agreed on key statistical analysis plan points that will cut the label database from 125 patients to 120. The company reported $246 million in cash.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENGN | -27.8% | +11.5% | +0.0% | +13.7% | -80.7% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -19.2% | +20.8% | +9.2% | +22.5% | -81.9% |